Safety and tolerability of CFI-400945, a first-in-class, selective PLK4 inhibitor in advanced solid tumours: a phase

Zachary W Veitch1, David W Cescon1,2, Trisha Denny2

  • 1Division of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.

Abstract

Insights

CFI-400945, a novel polo-like kinase 4 inhibitor, demonstrated acceptable safety and tolerability in a phase 1 trial for advanced solid tumors. The recommended phase 2 dose is 64 mg daily, with neutropenia as a key adverse event.

Area of Science:

  • Oncology
  • Pharmacology
  • Clinical Trials

Background:

  • CFI-400945 is a first-in-class oral inhibitor targeting polo-like kinase 4 (PLK4), an enzyme crucial for centriole duplication.
  • This study represents the first-in-human phase 1 clinical trial of CFI-400945 in patients with advanced solid tumors.

Purpose of the Study:

  • To determine the safety and tolerability of CFI-400945 in patients with advanced solid tumors.
  • To establish the recommended phase 2 dose (RP2D) and evaluate pharmacokinetic (PK), pharmacodynamic (PD), and preliminary efficacy of CFI-400945.

Main Methods:

  • A 3+3 dose escalation design was employed to evaluate continuous daily oral dosing of CFI-400945.
  • Safety was assessed using the Common Terminology Criteria for Adverse Events (CTCAE) v4.0, and efficacy was evaluated by Objective Response Rate (ORR) and Clinical Benefit Rate (CBR) per RECIST v1.1.

Main Results:

  • A total of 43 patients received escalating doses from 3 to 96 mg/day, with 9 patients in the 64 mg dose expansion cohort.
  • The recommended phase 2 dose (RP2D) was established at 64 mg/day after dose-limiting toxicities were observed at higher doses.
  • Neutropenia was the most common high-grade treatment-related adverse event (19%) at doses ≥64 mg. The drug exhibited a half-life of 9 hours.
  • Limited efficacy was observed, with an ORR of 2% and CBR of 6%, including one partial response and two cases of stable disease ≥6 months.

Conclusions:

  • CFI-400945 at 64 mg/day is well-tolerated, with dose-dependent neutropenia as a primary toxicity.
  • Favorable pharmacokinetic profiles were achieved with daily oral administration.
  • Low response rates were observed in this unselected patient population, suggesting the need for biomarker-guided or combination studies.

Related Concept Videos

Dose-Response Relationship: Selectivity and Specificity01:25

Dose-Response Relationship: Selectivity and Specificity

Drugs exert their therapeutic effects by interacting with receptors, enzymes, or ion channels that are present throughout the human body. The strength and duration of the interaction between a drug and its target receptor are characterized by the selectivity and specificity of the drug. Selectivity refers to a drug's strong preference for its intended target over other targets. For instance, isoprenaline, a non-selective β-adrenergic agonist, interacts with both β1- and...
9.6K
Phase Diagrams02:39

Phase Diagrams

A phase diagram combines plots of pressure versus temperature for the liquid-gas, solid-liquid, and solid-gas phase-transition equilibria of a substance. These diagrams indicate the physical states that exist under specific conditions of pressure and temperature and also provide the pressure dependence of the phase-transition temperatures (melting points, sublimation points, boiling points). Regions or areas labeled solid, liquid, and gas represent single phases, while lines or curves represent...
49.2K
Survey Safety01:28

Survey Safety

Surveying near highways, rough terrain, or power lines involves significant risks. Working along highways is particularly dangerous and requires the use of warning signs and flagmen. It is safest to avoid working directly on roads and use offsets whenever possible. When highway work is unavoidable, it must follow all safety guidelines. Surveyors should wear bright clothing, such as orange reflective vests, to ensure visibility to motorists, coworkers, and hunters. In construction zones, wearing...
374
Metallic Solids02:37

Metallic Solids

Metallic solids such as crystals of copper, aluminum, and iron are formed by metal atoms. The structure of metallic crystals is often described as a uniform distribution of atomic nuclei within a “sea” of delocalized electrons. The atoms within such a metallic solid are held together by a unique force known as metallic bonding that gives rise to many useful and varied bulk properties.
All metallic solids exhibit high thermal and electrical conductivity, metallic luster, and malleability....
20.5K
Structures of Solids02:22

Structures of Solids

Solids in which the atoms, ions, or molecules are arranged in a definite repeating pattern are known as crystalline solids. Metals and ionic compounds typically form ordered, crystalline solids. A crystalline solid has a precise melting temperature because each atom or molecule of the same type is held in place with the same forces or energy. Amorphous solids or non-crystalline solids (or, sometimes, glasses) which lack an ordered internal structure and are randomly arranged. Substances that...
17.5K
Phase Transitions02:31

Phase Transitions

Whether solid, liquid, or gas, a substance's state depends on the order and arrangement of its particles (atoms, molecules, or ions). Particles in the solid pack closely together, generally in a pattern. The particles vibrate about their fixed positions but do not move or squeeze past their neighbors. In liquids, although the particles are closely spaced, they are randomly arranged. The position of the particles are not fixed—that is, they are free to move past their neighbors to...
22.8K